GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (FRA:36X) » Definitions » Degree of Operating Leverage

Ascentage Pharma Group International (FRA:36X) Degree of Operating Leverage : -0.19 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Ascentage Pharma Group International's Degree of Operating Leverage for the quarter that ended in Dec. 2024 was -0.19. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Ascentage Pharma Group International's Degree of Operating Leverage or its related term are showing as below:

FRA:36X's Degree of Operating Leverage is ranked better than
57.55% of 881 companies
in the Biotechnology industry
Industry Median: -0.02 vs FRA:36X: -0.19

Ascentage Pharma Group International Degree of Operating Leverage Historical Data

The historical data trend for Ascentage Pharma Group International's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Degree of Operating Leverage Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only 6.01 0.20 -0.01 -0.48 -0.19

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.10 -0.48 -0.26 -0.19

Competitive Comparison of Ascentage Pharma Group International's Degree of Operating Leverage

For the Biotechnology subindustry, Ascentage Pharma Group International's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascentage Pharma Group International's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's Degree of Operating Leverage falls into.


;
;

Ascentage Pharma Group International Degree of Operating Leverage Calculation

Ascentage Pharma Group International's Degree of Operating Leverage for the quarter that ended in Dec. 2024 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -43.391 (Dec. 2024) / -107.469 (Dec. 2023) - 1 )/( 128.631 (Dec. 2024) / 28.509 (Dec. 2023) - 1 )
=-0.5962/3.5119
=-0.17***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Ascentage Pharma Group International  (FRA:36X) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Ascentage Pharma Group International Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascentage Pharma Group International Business Description

Traded in Other Exchanges
Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Ascentage Pharma Group International Headlines

No Headlines